Cardium Therapeutics
Biotechnology, 117 Centennial Student Un, San Diego, California, 56001, United States, 11-50 Employees
Who is CARDIUM THERAPEUTICS
Cardium Therapeutics is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address sign...
Read More
-
Headquarters: 117 Centennial Student Un, San Diego, California, 56001, United States
-
Employees: 11-50
-
Revenue: $500 Million to $1 Billion
Industry: Biotechnology
SIC Code: 8221
Does something look wrong? Fix it. | View contact records from CARDIUM THERAPEUTICS
Cardium Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to Cardium Therapeutics
Abeona Therapeutics
-
51-200
-
$ 25 Million to 50 Million
Helixmith
-
51-200
-
$ 1 Million to 5 Million
Sarepta Therapeutics
-
1001-5000
-
$ 250 Million to 500 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Cardium Therapeutics
Answer: Cardium Therapeutics's headquarters are located at 117 Centennial Student Un, San Diego, California, 56001, United States
Answer: Cardium Therapeutics's official website is https://cardiumthx.com
Answer: Cardium Therapeutics's revenue is $500 Million to $1 Billion
Answer: Cardium Therapeutics's SIC: 8221
Answer: Cardium Therapeutics has 11-50 employees
Answer: Cardium Therapeutics is in Biotechnology
Answer: Cardium Therapeutics top competitors include: Abeona Therapeutics , Helixmith , Sarepta Therapeutics
Answer: Cardium Therapeutics contact info: Phone number: Website: https://cardiumthx.com
Answer: Cardium Therapeutics is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardiums investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In May 2009, Cardium announced completion of the enrollment for the Matrix Phase 2b clinical study to evaluate the Excellarate product candidate as a treatment for patients with non-healing diabetic ulcers. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Companys biomedical investment portfolio.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month